Quick Answer
bioAffinity Technologies, Inc. reported R&D Expense of $1.38 million for fiscal year 2025.
bioAffinity Technologies, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.38M | -5.3% |
| 2024 | $1.46M | -0.5% |
| 2023 | $1.47M | +6.5% |
| 2022 | $1.38M | +36.8% |
| 2021 | $1.01M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $330.6K | +20.4% | +6.2% |
| June 30, 2025 | $311.4K | -22.6% | -15.2% |
| March 31, 2025 | $367.4K | -6.7% | +33.8% |
| September 30, 2024 | $274.5K | -16.9% | -31.8% |
| June 30, 2024 | $402.4K | +20.1% | +2.2% |
| March 31, 2024 | $393.6K | +6.5% | +19.1% |
| September 30, 2023 | $330.4K | +3.3% | -1.4% |
| June 30, 2023 | $335.1K | +34.9% | -9.3% |
- bioAffinity Technologies, Inc. showed a decrease of -5.3% in R&D Expense compared to the prior fiscal year.
- Over the 2021–2025 period, bioAffinity Technologies, Inc.’s r&d expense has grown by 37.3% (from $1.01 million to $1.38 million).
- The most recent figure is from bioAffinity Technologies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: